BCL2L1 and small cell lung carcinoma: These findings are corroborated by the transcriptomic profiling suggesting that BCL-XL is one of the highly expressed BCL-2 family anti-apoptotic proteins, and therefore, a promising therapeutic target in SCLC tumors [10–12].